Clin2
NCT06732388Possibly a fitRecruiting

Itraconazole with ablation to prevent esophageal cancer in Barrett's esophagus

Barrett EsophagusClinical Stage I Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Esophageal Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests if adding the antifungal drug itraconazole to standard ablation therapy can help prevent esophageal cancer in people with high-risk Barrett's esophagus. You must have a confirmed diagnosis of Barrett's esophagus with low- or high-grade dysplasia or early-stage cancer, and be planning to have ablation treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
76 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have Barrett's esophagus (at least 2 cm long) with low- or high-grade dysplasia or stage T1a esophageal cancer, and have not had previous treatment
  • You are 18 years or older
  • Your blood counts, liver, and kidney function are within safe limits (tests will be done to check)
  • You do not have serious heart problems, such as heart failure or a long QT interval on an EKG
  • You are not pregnant, breastfeeding, or planning to become pregnant; you must use effective non-estrogen birth control during and 2 months after the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04939051Recruiting· Phase 2
Obeticholic acid to prevent Barrett’s esophagus worsening

This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.

Kansas City, Kansas
NCT05563766Recruiting· Phase 2
Itraconazole added for treatable esophageal cancer before surgery

This study tests whether adding itraconazole (an anti-fungal medicine) to standard chemo-radiation before surgery increases the chance of complete tumor response. It’s for people with esophageal (or GE junction) cancer that can be removed with curative surgery after treatment.

Palo Alto, California
NCT07126535Recruiting
Radiofrequency ablation effects on the esophagus

This study looks at how radiofrequency ablation (RFA) affects the flexibility and lining of the esophagus in people with Barrett's esophagus and early cancer. It may help doctors understand how this treatment works.

Rochester, Minnesota
NCT07206589Not yet recruiting
New ways to screen for Barrett's esophagus

This trial tests two simple, non-surgical methods to look for Barrett's esophagus (a change in the lining of the swallowing tube) and early esophageal cancer. It is for people who are at higher risk or lower risk, but have never had Barrett's or cancer before.

Scottsdale, Arizona
NCT07212491Enrolling by invitation
New ways to detect early esophageal changes in Barrett's esophagus

This study tests a new, less invasive way to detect precancerous changes or early cancer in Barrett's esophagus. It uses a sponge or brush to collect cells from your esophagus during a routine endoscopy, which may help find problems earlier and avoid more invasive procedures.

Scottsdale, Arizona
NCT07455422Not yet recruiting
Barrett's esophagus: better risk prediction and its effect on quality of life

This trial tests a new risk model to predict if early Barrett's esophagus-related cancer may return. It also looks at how telling patients their risk affects their quality of life and fear of cancer. If you have Barrett's with a small, early cancer, this study may help decide the best follow-up plan for you.

Edegem, Antwerpen

Hear when a new Barrett Esophagus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.